PortfoliosLab logoPortfoliosLab logo
XHS vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

XHS vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Health Care Services ETF (XHS) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, XHS achieves a 26.76% return, which is significantly higher than IDNA's 25.19% return.


XHS

1D
0.45%
1M
10.64%
6M
21.53%
YTD
26.76%
1Y
45.58%
3Y*
13.33%
5Y*
4.53%
10Y*
9.10%

IDNA

1D
-1.42%
1M
9.31%
6M
16.31%
YTD
25.19%
1Y
54.34%
3Y*
12.07%
5Y*
-6.60%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

XHS vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
XHS
SPDR S&P Health Care Services ETF
26.76%18.83%1.76%5.15%-19.87%9.76%33.66%15.12%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
25.19%17.26%-0.72%-7.63%-42.28%-3.98%54.30%22.10%

Correlation

The correlation between XHS and IDNA is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.44

Correlation (3Y)
Calculated over the trailing 3-year period

0.54

Correlation (5Y)
Calculated over the trailing 5-year period

0.62

Correlation (All Time)
Calculated using the full available price history since Jun 13, 2019

0.60

The correlation between XHS and IDNA shifts across timeframes, from 0.44 (1 year) to 0.62 (5 years), reflecting how their relationship changes across market environments.

XHS vs. IDNA - Sectors Allocation Comparison


Sectors
XHS
IDNA

Healthcare

95.7%
99.5%

Financial Services

3.7%

-

Industrials

0.5%
0.3%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

XHS
95.7%
IDNA
99.5%

Financial Services

XHS
3.7%
IDNA

-

Industrials

XHS
0.5%
IDNA
0.3%

Basic Materials

XHS

-

IDNA

-

Communication Services

XHS

-

IDNA

-

Consumer Cyclical

XHS

-

IDNA

-

Consumer Defensive

XHS

-

IDNA

-

Energy

XHS

-

IDNA

-

Real Estate

XHS

-

IDNA

-

Technology

XHS

-

IDNA

-

Utilities

XHS

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XHS vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XHS
XHS Risk / Return Rank: 8888
Overall Rank
XHS Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
XHS Sortino Ratio Rank: 9090
Sortino Ratio Rank
XHS Omega Ratio Rank: 8989
Omega Ratio Rank
XHS Calmar Ratio Rank: 8686
Calmar Ratio Rank
XHS Martin Ratio Rank: 8484
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 8484
Overall Rank
IDNA Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 8484
Sortino Ratio Rank
IDNA Omega Ratio Rank: 7373
Omega Ratio Rank
IDNA Calmar Ratio Rank: 9393
Calmar Ratio Rank
IDNA Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XHS vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Health Care Services ETF (XHS) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


XHSIDNADifference
Sharpe ratioReturn per unit of total volatility

+0.38

Sortino ratioReturn per unit of downside risk

+0.40

Omega ratioGain probability vs. loss probability

1.45

1.34

+0.10

Calmar ratioReturn relative to maximum drawdown

3.82

5.12

-1.30

Martin ratioReturn relative to average drawdown

13.16

14.05

-0.89

XHS vs. IDNA - Sharpe Ratio Comparison

The current XHS Sharpe Ratio is 2.56, which is comparable to the IDNA Sharpe Ratio of 2.17. The chart below compares the historical Sharpe Ratios of XHS and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

XHS vs. IDNA - Drawdown Comparison

The maximum XHS drawdown since its inception was -39.32%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for XHS and IDNA.


Loading charts...

Drawdown Indicators


XHSIDNADifference

Max Drawdown

Largest peak-to-trough decline

-39.32%

-68.26%

+28.94%

Max Drawdown (1Y)

Largest decline over 1 year

-11.99%

-10.66%

-1.33%

Max Drawdown (3Y)

Largest decline over 3 years

-17.81%

-29.46%

+11.65%

Max Drawdown (5Y)

Largest decline over 5 years

-31.34%

-68.26%

+36.92%

Max Drawdown (10Y)

Largest decline over 10 years

-39.32%

Current Drawdown

Current decline from peak

-1.72%

-38.27%

+36.55%

Average Drawdown

Average peak-to-trough decline

-10.12%

-36.28%

+26.16%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.48%

3.88%

-0.40%

Volatility

XHS vs. IDNA - Volatility Comparison

The current volatility for SPDR S&P Health Care Services ETF (XHS) is 5.41%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.13%. This indicates that XHS experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XHSIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

5.41%

7.13%

-1.72%

Volatility (6M)

Calculated over the trailing 6-month period

12.81%

18.71%

-5.90%

Volatility (1Y)

Calculated over the trailing 1-year period

17.91%

25.18%

-7.27%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.22%

28.52%

-7.30%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.40%

29.49%

-7.09%

XHS vs. IDNA - Expense Ratio Comparison

XHS has a 0.35% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

XHS vs. IDNA - Dividend Comparison

XHS's dividend yield for the trailing twelve months is around 0.20%, less than IDNA's 0.86% yield.


PositionTTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
0.86%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
XHS
SPDR S&P Health Care Services ETF
0.20%0.27%0.38%0.23%0.19%0.20%0.23%2.37%0.34%0.22%0.28%0.93%

Frequently Asked Questions


XHS and IDNA have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.13%) compared to XHS (5.41%). In terms of maximum drawdown, XHS dropped -39.32% vs IDNA's -68.26%.

On 5-year performance, XHS leads with 4.53% vs -6.60% for IDNA. On fees, XHS is cheaper at 0.35% per year. On volatility, XHS has been the lower-risk option at 5.41%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, XHS has performed better with a 4.53% return vs -6.60%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

XHS is cheaper with a 0.35% expense ratio, compared with 0.47% for IDNA.

IDNA has the higher dividend yield at 0.86%, compared with 0.20% for XHS.

XHS tracks S&P Health Care Services Select Industry Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.35% for XHS and 0.47% for IDNA.

XHS currently has the higher Sharpe Ratio (2.56 vs 2.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for XHS and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer